

Amended

7-5/2013/EU/WC-0155

Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organisation  
(International Cell)

FDA Bhawan, Kotla Road,  
New Delhi -110002

Dated: 31 JUL 2024

To

M/s. Vamsi Labs Ltd.,  
A-14, A-15, A-31, A-32 & A-33,  
M.I.D.C. Area, Chincholi, Solapur-413 255,  
Maharashtra, India

**Subject: Amendment in Written Confirmation Certificate of M/s. Vamsi Labs Ltd., A-14, A-15, A-31, A-32 & A-33, M.I.D.C. Area, Chincholi, Solapur-413 255, Maharashtra, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b (2) (b) of Directive 2001/83/EC from India –reg.**

Sir,

Please refer to your application vide no. WC/ED/2023/7562 dated 20.09.2023 submitted for necessary amendment in WC certificate issued by this office.

In this regard, kindly find the enclosed amended Written Confirmation Certificate. The condition of the Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India will remain same.

Please acknowledge the receipt.

Yours faithfully



(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Vamsi Labs Ltd.,  
A-14, A-15, A-31, A-32 & A-33,  
M.I.D.C. Area, Chincholi, Solapur-413 255  
Maharashtra, India

2. Manufacturer's License Number: 25-PD/29

The address of the manufacturer mentioned in the Written Confirmation Certificate (WC-0155 valid up to 02.07.2025) is hereby amended as follows:


*In place of:*

A-14/15, M.I.D.C. Area, Chincholi, Solapur-413 255, Maharashtra, India

*Read as:*

A-14, A-15, A-31, A-32 & A-33, M.I.D.C. Area, Chincholi, Solapur-413 255, Maharashtra, India

All other conditions of Written Confirmation Certificate will remain same.

  
Signature



31 JUL 2024

**7-5/2013/EU/WC-0155**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organisation**  
**(International Cell)**

FDA Bhawan, Kotla Road,  
New Delhi-110002

Dated:

. 13 JUN 2022

To

**M/s. Vamsi Labs Ltd.,  
A-14/15, M.I.D.C. Area,  
Chincholi, Solapur-413 255,  
Maharashtra, India**

**Subject:- Written Confirmation of M/s. Vamsi Labs Ltd., A-14/15, M.I.D.C. Area, Chincholi, Solapur-413 255, Maharashtra, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.**

Sir,

Please refer to your application submitted to CDSCO, West Zone office Mumbai and the recommendation received from DDC(I), West Zone Mumbai on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall conform to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
1	08	13 JUN 2022	02.07.2025
2	01	13 JUN 2022	02.07.2025

Yours faithfully,



(Dr. V.G. Somani)  
Drugs Controller General (India)



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Vamsi Labs Ltd.,  
A-14/15, M.I.D.C. Area,  
Chincholi, Solapur-413 255,  
Maharashtra, India

2. Manufacturer's licence number: 25-PD/29

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

As per List enclosed as Annexure-1 & 2

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (=GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 29.06.2021 & 30.06.2021

The Written Confirmation remains valid until: 02<sup>nd</sup> July, 2025


The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation  
FDA Bhawan, Kotla Road,  
New Delhi- 110 002, India

Name and function of responsible person: Dr. V.G. Somani  
Drugs Controller General (India)

E-mail: dci@nic.in,  
Telephone no.: +91-11-23236965  
Fax no.: +91-11-23236973

Signature 

13 JUN 2022

Stamp of the authority and date





Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and address of site: M/s. Vamsi Labs Ltd.,  
A-14/15, M.I.D.C. Area,  
Chincholi, Solapur-413 255,  
Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Formoterol Fumarate Dihydrate EP	Manufacturing & Packing
2.	Salmeterol Xinafoate EP	Manufacturing & Packing
3.	Tiotropium Bromide Monohydrate EP	Manufacturing & Packing
4.	Haloperidol EP	Manufacturing & Packing
5.	Budesonide EP	Manufacturing & Packing
6.	Clenbuterol Hydrochloride EP	Manufacturing & Packing
7.	Fluticasone Propionate EP	Manufacturing & Packing
8.	Ipratropium Bromide EP	Manufacturing & Packing

ITEM(S) Eight (08) ONLY

The Written Confirmation remains valid until: 02<sup>nd</sup> July, 2025

Signature

Stamp of the authority and date



13 JUN 2022



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and address of site: M/s. Vamsi Labs Ltd.,  
A-14/15, M.I.D.C. Area,  
Chincholi, Solapur-413 255,  
Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Fenoterol Hydrobromide EP	Manufacturing & Packing

ITEM(S) One (01) ONLY

This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substances for the purpose of export only, as the above mentioned active substances are not approved for manufacture for sale in India.

The Written Confirmation remains valid until: 02<sup>nd</sup> July, 2025

Signature

Stamp of the authority and date



13 JUN 2022